EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.

CONCLUSION: Single-agent EV was generally well tolerated and provided clinically meaningful and durable responses in patients with mUC; survival data are encouraging. A pivotal phase II and a confirmatory phase III study are ongoing. PMID: 32031899 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research

Related Links:

Purpose: Immune checkpoint inhibitors (ICI) are now standard of care for advanced urothelial carcinoma (UC) that have failed platinum therapy. Atezolizumab and pembrolizumab are also approved in the first line setting for patients who are cisplatin-ineligible and are PD-L1 positive. This retrospective observational study aimed to describe the safety and efficacy of the ICI pembrolizumab in the real world setting at Guy ’s Hospital.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Synchronous chemotherapy with mitomycin C and 5-FU with radiotherapy may have an additional benefit over radiotherapy alone [1]. We looked into the rate of recurrence and median overall survival between these two groups of patients.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The use of FDG PET has become more readily available over the past 15 years. It can be used to aid initial staging of testicular tumours and also assess the response to treatment in the metastatic setting, especially as residual masses are frequently seen after chemotherapy. There have been some recent concerns that FDG PET used to assess for residual disease may have a low positive predictive value [1]. A retrospective audit was carried out to look at the performance of FDG PET in seminoma patients treated at the Edinburgh Cancer Centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The STAMPEDE trial has recently shown a benefit in overall survival by irradiating the prostate of patients with newly diagnosed metastatic prostate cancer [1]. This benefit was only shown in patients with low burden of metastatic disease, as per the CHAARTED criteria [2]. The current standard of care for these patients is androgen deprivation therapy ± docetaxel chemotherapy and radiotherapy to symptomatic areas of disease if required. The aim of this audit is to determine the potential number of men with low burden of metastatic disease who may require additional radiotherapy.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Sunitinib and pazopanib are standards of care for the first line treatment of metastatic renal cell carcinoma (mRCC) across the world. A phase III clinical trial has shown that pazopanib is non-inferior to sunitinib as first line treatment for mRCC. However, it is likely that the comparative efficacy of these drugs may differ in real world clinical practice. We aim to evaluate the outcomes and compare toxicities of patients with mRCC treated with first line sunitinib or pazopanib in regular clinical practice.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The management of metastatic urothelial cancer (mUC) is challenging. It is predominately a disease of the elderly population. The median age in the UK at which patients present with urothelial carcinoma is over 70 years. A large population of patients is unsuitable for cisplatin based therapy due to poor performance status and medical comorbidities. Overall outcome was poor due to limited treatment options. Recently, immune checkpoint inhibitors have improved disease response and survival.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Authors: Jia M, Xiong Y, Li M, Mao Q Abstract Chemotherapy is critical for the treatment of hepatocellular carcinoma (HCC). Despite the pro-apoptotic effects of corosolic acid (CA) treatment, its underlying mechanism is not completely clear. The aim of this study was to determine the molecular mechanism of CA in HCC treatment. MTT assay was used to determine the IC50 of CA. Immunoprecipitation and immunofluorescence were used to detect the interaction between and subcellular localization of Yes-associated protein (YAP) and mouse double minute 2 (MDM2). In addition, in vivo xenotransplantation was performed to asses...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
In conclusion, when treating elderly men with a smoking history, physicians need to carefully examine the walls of cystic airspaces on CT for fetal adenocarcinoma.Key pointsSignificant findings of the study•Pulmonary high‐grade fetal adenocarcinoma may be associated with emphysematous bullae manifesting as cystic air spaces as shown by computed tomography.What this study adds•When scanning by computed tomography, physicians should carefully examine the pulmonary cystic airspace walls in elderly men with a smoking history.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Alopecia | Brain | Cancer & Oncology | Carcinoma | Chemotherapy | Hepatocellular Carcinoma | Liver | Liver Cancer | Neurology | Peripheral Neuropathy | Study | Urology & Nephrology